title: Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?
abstract: OBJECTIVE
  The aim of the study was to investigate the effect of chemotherapy treatment with ABVD on brain glucose metabolism in patients with Hodgkin's disease (HD).
  
  
  METHODS
  A total of 49 patients (23 men, 26 women; mean age 32±9 years) diagnosed with HD were included in the study. All of them underwent a baseline (PET0) and an interim (PET2) 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) PET/computed tomography (CT) brain scan. All patients were treated after PET0 with two cycles of ABVD consisting of doxorubicin (adriamycin), bleomycin, vinblastine, and dacarbazine for 2 months. Thirty-five patients were evaluated further 15±6 days after four additional cycles (PET6). Differences in brain (18)F-FDG uptake were analyzed by statistical parametric mapping (SPM2).
  
  
  RESULTS
  Compared with PET0, PET2 showed a significantly higher metabolic activity in the right angular gyrus (Brodmann area 39) and a significant metabolic reduction in Brodmann areas 10, 11, and 32 bilaterally. All these changes disappeared at PET6.
  
  
  CONCLUSIONS
  Our results support the conclusion of a very limited impact of ABVD chemotherapy on brain metabolism in patients with HD.
authors.affiliation: Department of Biopathology and Diagnostic Imaging, University Tor Vergata cInstitute of Cognitive Sciences and Technologies, CNR, Rome, Italy. agostino.chiaravalloti@gmail.com
authors.forename: Agostino
authors.initials: A
authors.lastname: Chiaravalloti
authors.forename: Marco
authors.initials: M
authors.lastname: Pagani
authors.forename: Barbara
authors.initials: B
authors.lastname: Di Pietro
authors.forename: Roberta
authors.initials: R
authors.lastname: Danieli
authors.forename: Mario
authors.initials: M
authors.lastname: Tavolozza
authors.forename: Laura
authors.initials: L
authors.lastname: Travascio
authors.forename: Cristiana R
authors.initials: CR
authors.lastname: Caracciolo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Simonetti
authors.forename: Maria
authors.initials: M
authors.lastname: Cantonetti
authors.forename: Orazio
authors.initials: O
authors.lastname: Schillaci
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001692:Biological Transport / Q000187:drug effects; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism*; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019788:Fluorodeoxyglucose F18; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D005947:Glucose